Tech Company Financing Transactions
Ocugen Funding Round
Ocugen, based in Malvern, received $5 million in funding from private investors.
Transaction Overview
Company Name
Announced On
2/16/2018
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 2 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5 Great Valley Pkwy. 160
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Not Recorded
Overview
Ocugen is advancing two novel biologicals and a marketed drug product as a re-purposed drug under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway to treat sight threatening ocular disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shankar Musunuri
Chief Financial Officer
Sanjay Subramanian
Chief Medical Officer
Mohamed Genead
Chief Scientific Officer
Rasappa Arumugham
Controller
Jessica Crespo
VP - Regulatory Affairs
Vijay Tammara
Browse more venture capital transactions:
Prev: 2/16/2018: Roostify venture capital transaction
Next: 2/16/2018: Transparency Life Sciences venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs